Skip to content
DraconiticResearch
Search Sources API
206,690 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BYAntioxidants (Basel, Switzerland)

Hypoxia-Driven Extracellular Vesicle Signaling in Lung Cancer Progression, Immune Evasion, and Therapeutic Resistance

Read full textPDFCite

Related

  1. MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance
    Pierre Sohier, Jérémy H Raymond, Zackie Aktary +13
    Cell Death and DifferentiationPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationHAL
  2. Adaptive Mitochondrial Specialization in Lung Adenocarcinoma: Redox Homeostasis, Hypoxia Adaptation, and Therapeutic Resistance
    Manuel Castillejos-López, Ulises Barrera-Elizalde, Edgar Flores-Soto +10
    Antioxidants (Basel, Switzerland)Peer-reviewedCC BYFull textEurope PMC
  3. p38α Signaling Is Associated with Pancreatic Ductal Adenocarcinoma Progression and Represents a Potential Therapeutic Vulnerability
    Ilaria Grassi, Elisabetta Di Nicola, Erica Candela +8
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  4. PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance
    Fabiana Napolitano, Nisha Unni, Carlos L. Arteaga
    The Journal of clinical investigationPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Extracellular Vesicle-Associated Epithelial–Mesenchymal Plasticity (EMP) as a Driver of Metastatic Evolution and Therapeutic Resistance in Ovarian Cancer
    Julia N. Hibbard, Ata Ullah, Farzana Alam
    CancersPeer-reviewedCC BY 4.0OncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{anon2026hypoxiadriven,
  title = {{Hypoxia-Driven Extracellular Vesicle Signaling in Lung Cancer Progression, Immune Evasion, and Therapeutic Resistance}},
  journal = {Antioxidants (Basel, Switzerland)},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13701708},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Hypoxia-Driven Extracellular Vesicle Signaling in Lung Cancer Progression, Immune Evasion, and Therapeutic Resistance
PY  - 2026
DA  - 2026/10/01
JO  - Antioxidants (Basel, Switzerland)
UR  - https://europepmc.org/article/PMC/PMC13701708
SN  - 2076-3921
ER  -